At the news
? NEUTRALIMPACT 4/10 425 filed Jun 5, 2026 at 08:00 ET
Pulmatrix filed a Rule 425 communication on behalf of Eos SENOLYTIX, announcing preclinical data for PTC-2105 at the Sachs Obesity Forum. The filing reiterates the pending merger with Pulmatrix (expected Q3 2026) and highlights PTC-2105's potential in body composition and survival. No new financial terms or deal changes were disclosed.
- Eos SENOLYTIX presented preclinical data for PTC-2105 at the Sachs 2nd Annual Obesity & Cardiometabolic Innovation Forum on June 5, 2026.
- PTC-2105 demonstrated reductions in fat mass greater than GLP-1s, gains in lean mass, and improved physical function in preclinical studies.
- In naturally aged mice, 40% of the PTC-2105 25 mg/kg cohort remained alive at 146 weeks vs. 100% mortality in controls by 137 weeks (p=0.0142).
- The merger between Pulmatrix and Eos was announced March 26, 2026, expected to close in Q3 2026, with combined company trading under ticker MTXL.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access